Clinical Services

Clinigen is the global market leader in the specialist supply, packaging, distribution and management of quality-assured comparator medicines and services to clinical trials and IITs.

Clinical Services aims to be the market leader in servicing clinical trials and supplying quality-assured comparator medicines internationally. Its strategic focus is on:

  • Establishing Clinigen with customer compounds earlier in the product lifecycle
  • Improving visibility and quality of revenue streams through diversification of customer base, longer-term contracts and exclusive supply arrangements
  • Presenting product opportunities to Unlicensed Medicines business operation

Clinical Services represents 18% of adjusted Group gross profit. This operation increased gross profit by £19.2m to £33.2m (2018: £14.0m) due to the acquisition of CSM and strong organic growth in CTS. Adjusted gross profit on an organic basis increased by 23%.

£140.7m

Revenue (£m)

33.2

Adjusted Gross Profit (£m)

427

Number of clients

1.5m

Units shipped

40

Countries shipped to

View Clinical Services


Unlicensed Medicines

Clinigen is the global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Group manages Managed Access Programs (‘MAPs’) to innovative new medicines and provides global access to medicines which remain unlicensed at the point of care.

Clinigen is the international leader in ethically sourcing, managing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Group manages MAPs to innovative new medicines and provides global access to medicines which remain unlicensed at the point of care.

Its aim is to be the first point of call for HCPs to source hard to access, unlicensed medicines through its strategy of:

  • Developing a rich pipeline based on industry trends and innovation
  • Providing a world-class customer service to HCPs, sourcing hard to access medicines for their patients
  • Converting MAPs to long-term exclusive supply agreements in Global Access

The Unlicensed Medicines operation represents 38% of adjusted Group gross profit. The operation increased its gross profit by 12% to £69.7m (2018: £62.1m) due to a strong performance in Managed Access, in the AAA regions in Global Access, and a full period’s contribution from Quantum. Adjusted gross profit on an organic basis increased by 3%.

£205.9

Revenue (£m)

£69.7

Adjusted Gross Profit (£m) +12%

192

Number of exclusive supply agreements

117

Number of managed access programs

2.9m

Units shipped

100

Countries shipped to

View Unlicensed Medicines 


Commercial Medicines

Clinigen acquires global rights to niche hospital only and critical care products, revitalising these assets around the world and returning them back to sustained growth. It also provides access to licensed and branded generic medicines in the AAA region.

The Group also has an UL2L strategy, where it looks to take unlicensed medicines with commercial potential and licences them, helping to address unmet medical need and allowing the Group to capitalise on its market-leading positions.

The strategy for Commercial Medicines is threefold in order to build a portfolio that can deliver sustainable growth through:

  • Continued revitalisation/growth of current portfolio of niche hospital-only and critical care products, coupled with selective product acquisitions
  • Being the licensing partner of choice for pharmaceutical and biotech clients in non-core territories through regional licensing agreements
  • Developing a long-term pipeline of medicines and launch licensed products through the UL2L model.

Commercial Medicines represents 44% of adjusted Group gross profit. Gross profit on an adjusted basis increased 24%, supported by the acquisitions of Proleukin and Imukin, and a full period’s contribution from Quantum. On an organic basis, gross profit decreased 7% due to competitive pressure primarily on sales of Foscavir®.

£110.3

Revenue (£m)

£79.4

Adjusted Gross Profit (£m) +24%

262

Number of local, regional and global assets under management*

2.0m

Units shipped

50

Countries shipped to

*Number of local, regional and global assets under management includes all products in the Commercial Medicines portfolio.

View Commercial Medicines